Effects of selective estrogen receptor modulator raloxifene plus 17-beta estradiol in aorta and mammary gland of female experimental atherosclerosis rabbits and possible involvement of ERK signal transduction pathway.
The present study investigated the effects of raloxifene, a second generation selective estrogen receptor modulator (SERM), plus 17-betaE2 on aortic atherosclerosis and mammary gland hyperplasia in ovariectomized, cholesterol-fed rabbits. Following 10 weeks of raloxifene, 17-betaE2, or raloxifene plus 17-betaE2 administration, serum total cholesterol, triglyceride, low density lipoprotein were significantly decreased in the drug groups compared to the placebo group. Consistent with serum lipid results, the total lesion area for each aorta of the drug groups decreased significantly as compared to the placebo group. HE staining of aorta paraffin section showed that in the drug groups the endothelial monolayer was almost continuous. While in mammary gland, HE staining of paraffin sections indicated the hyperplasia of epithelial cells (in 17-betaE2 group) was obviously inhibited in raloxifene plus 17-betaE2 group. In cultured vascular smooth muscle cell (VSMC), the results of MTT and [3H]TdR incorporation showed that the drug groups could inhibit AngII-induced proliferation of VSMC. Western blotting proved that raloxifene plus 17-betaE2 inhibited the expression of phosphorylated ERK protein, similar to 17-betaE2 but different from raloxifene. This effect was inhibited by PD98059 (inhibitor of MAPK) or ICI182780 (ER antagonist). In conclusion, this study suggests that SERM raloxifene plus 17-betaE2 improves the lipid metabolism and relieves the aorta changes of female experimental atherosclerosis rabbits, which are partly implemented by the inhibition of VSMC growth through ERK cascade. The hyperplasia of mammary gland epithelial cells could be significantly inhibited by raloxifene plus 17-betaE2.
Xiang
Qiu Ling
QL
Department of Physiology, Sun Yat-Sen Medical College, Sun Yat-Sen University, Guangzhou, Guangdong, People's Republic of China.
Chen
Yu
Y
Lin
Gui Ping
GP
Tan
Zhi
Z
Wang
Ting Huai
TH
D000818:Animals; D001011:Aorta / Q000187:drug effects*; D050197:Atherosclerosis / Q000188:drug therapy* / Q000473:pathology; D015153:Blotting, Western; D004347:Drug Interactions; D004958:Estradiol / Q000494:pharmacology* / Q000627:therapeutic use; D048049:Extracellular Signal-Regulated MAP Kinases / Q000187:drug effects; D005260:Female; D006965:Hyperplasia / Q000188:drug therapy; D008055:Lipids / Q000097:blood; D008321:Mammary Glands, Animal / Q000187:drug effects / Q000473:pathology*; D009131:Muscle, Smooth, Vascular / Q000187:drug effects; D011817:Rabbits; D020849:Raloxifene Hydrochloride / Q000494:pharmacology*; D020845:Selective Estrogen Receptor Modulators / Q000494:pharmacology* / Q000627:therapeutic use; D015398:Signal Transduction / Q000187:drug effects; D013778:Tetrazolium Salts; D013844:Thiazoles; D013936:Thymidine
D008055:Lipids; D020845:Selective Estrogen Receptor Modulators; D013778:Tetrazolium Salts; D013844:Thiazoles; D020849:Raloxifene Hydrochloride; D004958:Estradiol; D048049:Extracellular Signal-Regulated MAP Kinases; C022616:thiazolyl blue; D013936:Thymidine